Cancer
Breast cancer in Tianjin
天津 乳腺癌
4 hospitals in Tianjin
Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Tianjin may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 246 papers led
- 20 papers ledNo open trial led
- 20 papers ledNo open trial led
- 5 papers led
Breast cancer in every city Tianjin on the disease page, with the national map
open trials on breast cancer with a hospital in Tianjin
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Tianjin as lead sponsor or study site. 21 of them are led by a hospital in Tianjin. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07321015
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingNeoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07372079
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07413939
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan
- RecruitingElectroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07490938
Age 18 years to 75 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesTianjin, Wuhan, Xining
- RecruitingBGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07492641
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07498478
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan
- RecruitingClinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07697443
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Meizhou, Tianjin, Wuhan
- RecruitingAnalysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07763587
Age 18 years to 70 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 1 listed hospital as study siteTianjin
- RecruitingRisk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient Adherence
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07817056
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingPhase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07817082
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingBGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06756932
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou
- RecruitingPhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06757634
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shenyang, Tianjin, Weifang, Xi'an, Xinxiang, Yangzhou, Zhengzhou
- RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06790693
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang
- RecruitingA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06891833
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Phase
- Phase 2/Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06926868
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesAnyang, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingA Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06974929
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07003074
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Hefei, Jinan, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Urumqi, Wuhan
- RecruitingClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07008976
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Fuzhou, Haikou, Hefei, Lanzhou, Linyi, Nanchang, Nanchong, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Zhengzhou
- RecruitingA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07043725
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou
- RecruitingTQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07047365
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou
- RecruitingA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07100106
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Jinan, Nanning, Shanghai, Tianjin
- RecruitingA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07114601
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07169994
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang
- RecruitingA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07174336
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan
- RecruitingAn Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07222267
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Xiamen
- RecruitingObservation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT07350928
Age 20 years to 70 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingReal-world Studies of CDK4/6 Inhibitors
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07407439
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingLevel I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
- Phase
- N/A
- Started
- 2025-10
- Posted
- Registry
- NCT07469267
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 12 listed hospitals as study sitesChangsha, Guiyang, Hangzhou, Harbin, Jinan, Ningbo, Shanghai, Shijiazhuang, Tianjin, Wuhan
- RecruitingA Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07673029
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou
- RecruitingEntinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07708194
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06210776
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai
- RecruitingBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase
- Phase 1/Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06324357
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingDalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06495515
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingEliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06498154
Age 18 years to 70 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06878625
Age 18 years to 70 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel
- Phase
- N/A
- Started
- 2024-09
- Posted
- Registry
- NCT07019233
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05646862
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan
- RecruitingEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT05696626
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingSafety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05860465
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan
- RecruitingEfficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT05872347
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05894239
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Hangzhou, Jinan, Luoyang, Nanchang, Nanning, Shijiazhuang, Tianjin, Wuhan
- RecruitingA Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06064812
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06079983
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingNeoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
- Phase
- Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT06227117
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Tianjin
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- Not yet recruitingEffect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07481903
Age 18 years to 75 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesBeijing, Nanjing, Tianjin
- Not yet recruitingExploratory Study of SHR-A1811 Via Different Administration Routes in Patients
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07560475
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingA Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2026-11
- Posted
- Registry
- NCT07894328
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingStudy on the Construction and Implementation Effect of a Traditional Chinese Medicine-Based Mental-Physical Comorbidity Linked Health-Management System of "Hospital-Community-Family" for Breast Cancer Patients
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07942103
Age 18 years to 70 years; women only (registered criteria)
Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin
- Not yet recruitingClinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07005583
Age 18 years to 75 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingSacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07139470
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingSacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07153965
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingEvaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07246317
Age 18 years to 70 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 4 listed hospitals as study sitesGuangzhou, Luoyang, Shijiazhuang, Tianjin
- Enrolling by invitationA Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07376629
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou
- Enrolling by invitationImpact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT07409298
Age 18 years to 80 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Tianjin
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Logistics University of Chinese People中国人民武装警察部队特色医学中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beichen District Tradicine Chinese Medicine Hospital天津市北辰区中医医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Cangzhou Central Hospital沧州市中心医院 | 2 | none | none | 11 | 30 | none | 20 | 14 | none | 0 | none | 7 | 1 | 2 | 1 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 6 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Nankai University天津市人民医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Teaching Hospital, Tianjin University of Traditional Chinese Medicine天津中医药大学第一附属医院 | none | none | none | none | 264 open | none | 54 open | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Haihe Hospital天津市海河医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所) | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 4728 open | 1312 open | 489 open | none | 3432 open | 1 | 255 open | none | 0 | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | 1 | none | none | none | 0 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | |
| Pingjin Hospital平津医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine天津中医药大学第二附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Hospital of Tianjin Medical University天津医科大学第二医院 | none | none | none | 3 | 8 | none | none | none | none | none | none | 0 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 23 | 4 | none | none | none | none | 1 | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| TEDA International Cardiovascular Hospital泰达国际心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | 15 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| TEDA International Cardiovascular Hospital泰达国际心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Baodi Hospital天津市宝坻区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Chest Hospital天津市胸科医院 | none | none | none | none | 39 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 362 open | 4 | none | none | none | none | 3 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Children's Hospital天津市儿童医院 | none | none | none | none | none | none | none | none | 2 | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 17 | none | none | none | none | none | none | none | none | none | none | 0 | none | 2 | none | none | 0 | none | none | none | none | none | 1 | 2 | none | none | none | none | none | none | none | |
| Tianjin Eye Hospital天津市眼科医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Fifth Central Hospital天津市第五中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin First Central Hospital天津市第一中心医院 | none | none | 45 | none | 191 open | none | none | none | 1 | none | 1 | 3 | 0 | 0 | none | 8 | 2 | none | none | 21 | none | none | none | 0 | none | none | none | none | none | none | 9 | 3 | 3 | none | none | 1 | none | 2 | none | 0 | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Fourth Central Hospital天津市第四中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Hospital天津市天津医院 | none | none | none | none | none | none | none | none | none | none | none | 10 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | 1 | none | none | none | none | none | none | 0 | none | 1 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Huanhu Hospital天津市环湖医院 | none | none | none | none | none | none | none | 151 open | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 12 open | none | 02 open | none | none | none | none | none | none | 2 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Jinnan Hospital天津市津南医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Medical University Baodi Hospital天津医科大学附属宝坻医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院 | 7 | 4712 open | 8811 open | 786 open | 25830 open | 7112 open | 24617 open | 14 | 1 | none | 1 | 18 | 2 | 211 open | 1 | 101 open | none | none | none | 569 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Tianjin Medical University Eye Hospital天津医科大学眼科医院 | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Medical University General Hospital天津医科大学总医院 | 1 | 5 | 22 | 30 | 124 | 10 | 20 | 783 open | 1 | 1 | none | 3 | 2 | 0 | none | 271 open | 01 open | 23 | none | 71 open | none | none | none | 1 | none | 222 open | 3 | 211 open | 2 | none | none | 16 | 1 | none | none | 0 | none | 7 | none | 1 | 1 | none | none | 2 | none | 1 | 10 | none | none | 4 | 7 | 1 | none | 0 | none | none | 0 | 3 | none | none | none | |
| Tianjin Nankai Hospital天津市南开医院 | none | none | none | none | none | 7 | none | none | none | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Port Hospital天津港口医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Second People's Hospital天津市第二人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Third Central Hospital天津市第三中心医院 | none | none | 30 | none | none | none | none | none | none | none | none | 0 | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Traditional Chinese Medicine Affiliated Hospital天津市中医药研究院附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Tianjin.
- Neuroblastoma 1
- Multiple myeloma 4728 open
- B-cell acute lymphoblastic leukaemia 1312 open
- Aplastic anaemia 489 open
- Lymphoma 3432 open
- Beta thalassaemia 1
- Haemophilia A 255 open
- Thrombotic thrombocytopenic purpura 0
- Fanconi anaemia 3
- Amyotrophic lateral sclerosis 1
- Duchenne muscular dystrophy 1
- Gaucher disease 0
- Primary sclerosing cholangitis 1
- Hepatocellular carcinoma 45
- Lung cancer 191 open
- Hepatoblastoma 1
- Chordoma 1
- Osteosarcoma 3
- Gastrointestinal stromal tumour 0
- Neuroblastoma 0
- Multiple myeloma 8
- B-cell acute lymphoblastic leukaemia 2
- Lymphoma 21
- Thrombotic thrombocytopenic purpura 0
- Biliary atresia 9
- Coronary heart disease 3
- Congenital heart disease 3
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 0
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 7
- Oesophageal squamous cell carcinoma 4712 open
- Hepatocellular carcinoma 8811 open
- Stomach cancer 786 open
- Lung cancer 25830 open
- Pancreatic cancer 7112 open
- Breast cancer 24617 open
- Glioma 14
- Hepatoblastoma 1
- Chordoma 1
- Osteosarcoma 18
- Gastrointestinal stromal tumour 2
- Neuroblastoma 211 open
- Ewing sarcoma 1
- Multiple myeloma 101 open
- Lymphoma 569 open
- Familial adenomatous polyposis 1
- Nasopharyngeal carcinoma 1
- Oesophageal squamous cell carcinoma 5
- Hepatocellular carcinoma 22
- Stomach cancer 30
- Lung cancer 124
- Pancreatic cancer 10
- Breast cancer 20
- Glioma 783 open
- Hepatoblastoma 1
- Retinoblastoma 1
- Osteosarcoma 3
- Gastrointestinal stromal tumour 2
- Neuroblastoma 0
- Multiple myeloma 271 open
- B-cell acute lymphoblastic leukaemia 01 open
- Aplastic anaemia 23
- Lymphoma 71 open
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 222 open
- IgG4-related disease 3
- Myasthenia gravis 211 open
- Moyamoya disease 2
- Coronary heart disease 16
- Congenital heart disease 1
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 7
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 1
- Duchenne muscular dystrophy 2
- Alport syndrome 1
- IgA nephropathy 10
- Osteogenesis imperfecta 4
- Primary biliary cholangitis 7
- Primary sclerosing cholangitis 1
- Hirschsprung disease 0
- Familial adenomatous polyposis 0
- Leber hereditary optic neuropathy 3
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for breast cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Tianjin on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.